All companies
Visit website
Chow 420
OperatingVLISO, inc.
Biotech · Founded 2017
The go-to place for all CBD brands
Post-money valuation ⓘ
$13.5M
As of Aug 2024 · from Chow 420 Common Stock 4 · pre-money + amount raised, not a traded price
Total raised
$1,959,328
Across 4 rounds since 2019
Latest share price
$1.18
Chow 420 Common Stock 4 offering price
Financials
FY2017–FY2023 · from SEC filings · hover any figure for its source$0
−$21K
2017
$0
2018
$16K
−$215
2019
$5K
−$185K
2020
$14K
−$168K
2021
$194K
−$457K
2022
$302K
−$69K
2023
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
Income statement
Revenue
$0
$0
$16,443
$5,028
$13,710
$193,588
$301,808
Cost of goods sold
$0
$0
$0
$164
$850
$33,314
$127,787
Gross margin
—
—
100%
97%
94%
83%
58%
Net income
-$20,867
$0
-$215
-$185,445
-$168,017
-$456,757
-$68,964
Taxes paid
$0
$0
$0
$0
$0
$0
$0
Balance sheet
Cash
$1,260
$0
$400
$634,029
$818,972
$145,107
$58,685
Accounts receivable
$0
$0
$0
$0
$0
$0
$0
Total assets
$9,341
$0
$2,550
$658,603
$849,171
$467,179
$498,737
Short-term debt
$0
$0
$0
$0
$0
$0
$0
Long-term debt
$0
$0
$30,000
$30,000
$0
$0
$0
Total liabilities
$0
$0
$30,000
$30,000
$0
$0
$0
Other
Headcount
—
2
2
5
7
7
7
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$6.1M
post-money
$17.8M
post-money
$19.1M
post-money
$13.5M
post-money
Chow420 Stock 1
Reg CF Offering (2021)
Chow420 Common Stock 3
Chow 420 Common Stock 4
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $78.7K / $618KInvestors 122Post-money $13.5M
Raised $90.4K / $250KInvestors 112Post-money $19.1M
Reg CF Offering (2021)Closed
Reg CF annual-report compliance
Not required3+ reports filed & assets ≤ $10M
Filed 5 of 7 annual reports (FY2019–FY2025)
3,179 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 29 filings on EDGARSource: ManualCIK 0001784430Share price $1.18
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.